Raising Quality, Improving Lives
Xcision Medical Systems, LLC is a medical technology company developing advanced stereotactic radiotherapy solutions with the potential to significantly improve the quality of cancer care as well as the lives of patients and their loved ones.
The company’s technology is designed to extend the benefits of radiation oncology to more patients and enable precision noninvasive treatments that allow patients to return to living fuller lives more quickly with less discomfort after receiving a cancer diagnosis.
Advancing Stereotactic Radiotherapy
Xcision’s initial focus is on breast cancer, using stereotactic radiotherapy to deliver focused radiation to a partial volume of the breast in conjunction with breast conserving treatment. The company’s first product, GammaPod™, is a new stereotactic radiotherapy system optimized for the treatment of breast cancer.
The delivery of higher doses in one or several large fractions differentiates stereotactic radiotherapy from conventional techniques. The system has been developed based on a patent licensed from the University of Maryland School of Medicine.
Driving Value in Cancer Care
Technologies like the GammaPod have the potential to revolutionize the management of localized breast cancer and create genuine value for patients, providers and payers.
Through the GammaPod Research Consortium, clinical researchers are developing new protocols to evaluate the potential of shortening the course of treatments as well as the potential to deliver doses at ablative levels prior to surgery. Upcoming trials will collect data on patient reported outcomes, side effects and the efficacy of adjuvant and neoadjuvant radiation.
